SK pharmteco Invests US$260 million to Expand Peptide Production in South Korea
Introduction:
SK pharmteco invests US$260 million to expand its small molecule and peptide production capabilities in South Korea.
Features:
A new five-story, 136,000 square-foot multipurpose building is being developed to enhance capacity and capabilities, enabling faster turnaround times, greater flexibility, and improved quality.
The 135,800-square-foot facility will accommodate eight production units, each with the capability to produce tens of metric tons annually.
It will also feature state-of-the-art peptide R&D facilities, CGMP kilo labs, and a CGMP pilot plant, providing the flexibility to support both early-stage clinical development and commercial production.
Additionally, the investment covers the construction of the foundation for a sixth manufacturing plant, providing room for future capacity expansion.
This development strengthens its presence in Asia, aligning with its global expansion strategy and reinforcing its role in pioneering treatments.
This expasnion plans to hire over 300 new employees at the Sejong site to support this growth, demonstrating its adaptability and commitment to reliability in a dynamic industry.
Specifications:
| Name | SK pharmteco |
| Type | Expansion |
| Budget | US$260 Million |
| Year | 2026 |
